LC
ITCI

Lindbrook Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Lindbrook Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$48.4K Sell
367
-68
-16% -$8.47K ﹤0.01% 1026
2024
Q4 		$36.3K Buy
435
+65
+18% +$5.34K ﹤0.01% 951
2024
Q3 		$27.1K Buy
370
+35
+10% +$2.63K ﹤0.01% 1127
2024
Q2 		$22.9K Sell
335
-53
-14% -$3.68K ﹤0.01% 1163
2024
Q1 		$26.9K Hold
388
– – ﹤0.01% 1064
2023
Q4 		$27.8K Sell
388
-7
-2% -$403 ﹤0.01% 1007
2023
Q3 		$20.6K Buy
395
+71
+22% +$4.14K ﹤0.01% 1049
2023
Q2 		$20.5K Buy
324
+31
+11% +$1.93K ﹤0.01% 1074
2023
Q1 		$15.9K Sell
293
-11
-4% -$532 ﹤0.01% 1187
2022
Q4 		$16.1K Sell
304
-181
-37% -$9.07K ﹤0.01% 1174
2022
Q3 		$23K Buy
485
+122
+34% +$6.37K ﹤0.01% 932
2022
Q2 		$21K Buy
363
+296
+442% +$16.8K ﹤0.01% 957
2022
Q1 		$4K Buy
+67
New +$3.48K ﹤0.01% 1759

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lindbrook Capital's ITCI Position: Q1 2025 in Review

Lindbrook Capital reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 16% in Q1 2025, selling an estimated $8.47K and leaving 367 shares worth $48.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

Lindbrook Capital first reported a position in ITCI in Q1 2022 and has held it in 13 quarters since. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Lindbrook Capital held 367 shares of Intra-Cellular Therapies Inc. worth $48.4K as of Q1 2025.
  • Lindbrook Capital sold 68 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $8.47K.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1026 holding.
  • Lindbrook Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and has held it in 13 quarters since.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.